ロード中...
Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
INTRODUCTION: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance ≤50 mL/min). In this post hoc analysis, we assessed...
保存先:
| 出版年: | Diabetes Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5014790/ https://ncbi.nlm.nih.gov/pubmed/27402391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-016-0184-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|